The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.
Pancreatic Ductal Adenocarcinoma
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: * to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) * to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible reappearance of the tumor (second part) Participants will receive: i) a therapeutic protein vaccine ATP150 or ATP 152 ii) a viral vector VSV-GP154 iii) an immune checkpoint inhibitor Ezabenlimab In the second part of the study, researchers will compare treatment group versus observational group.
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
-
USC/Norris Comprehensive Center, Los Angeles, California, United States, 90033
University of California Los Angeles (UCLA), Los Angeles, California, United States, 90095
University of Colorado Hospital, Aurora, Colorado, United States, 80045
University of Florida, Gainesville, Florida, United States, 32610-0278
Orlando Health, Orlando, Florida, United States, 32806
Karmanos Cancer Institute, Detroit, Michigan, United States, 48201
NYU Langone Health, New York, New York, United States, 10016
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030
START - South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States, 78229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Amal Therapeutics,
Paul Oberstein, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health
Shubham Pant, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center
2027-03